{"id":"W2969960972","doi":"10.1016/j.jaci.2019.08.013","title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","year":2019,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":271,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"Maruho; Chugai Pharmaceutical; LEO Pharma; AbbVie; Glenmark Pharmaceuticals; UCB Pharma; Galápagos; Amgen; Boehringer Ingelheim; Les Laboratories Pierre Fabre; Janssen Biotech; Santen; Novartis; Celgene; Kiniksa Pharmaceuticals; Beiersdorf; MedImmune; Sanofi; Regeneron Pharmaceuticals; Pfizer; Almirall; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Eczema Area and Severity Index; Placebo; Medicine; Atopic dermatitis; Randomized controlled trial; Dosing; Internal medicine; Gastroenterology; Adverse effect; Clinical endpoint; Severity of illness; Corticosteroid; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003697249,0.0001393875,0.001340517,0.0001485041,0.00002903985,0.000006738291,0.00008772202,0.0001918485,0.0001030238],"category_scores_gemma":[0.0003266861,0.00009330577,0.0001043438,0.00008442187,0.000234577,0.0001040583,0.00005526771,0.0004311823,0.000003947428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009612884,"about_ca_system_score_gemma":0.0001250931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003092596,"about_ca_topic_score_gemma":0.0001131962,"domain_scores_codex":[0.997952,0.0004491601,0.001134216,0.0001748287,0.0001239797,0.0001657699],"domain_scores_gemma":[0.9984673,0.0006553439,0.0004140341,0.0001697977,0.0001661474,0.0001273802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6886627,0.01111479,0.2750783,0.0001808102,0.006049436,0.002031052,0.003000254,0.00004744953,0.00002499095,0.0002516094,0.0004952882,0.01306331],"study_design_scores_gemma":[0.6269407,0.006664243,0.3593166,0.0005794275,0.0002709551,0.003470427,0.001814177,0.0001897809,0.00001811955,0.0003779216,0.0002187222,0.0001389289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952641,0.002808993,0.00001500198,0.0009263213,0.0001591422,0.0005090221,0.000001652553,0.000004733816,0.0003110211],"genre_scores_gemma":[0.996632,0.002671769,0.0001446373,0.0004116226,0.00002764324,0.000005900499,0.000001940136,0.000008675664,0.0000958195],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08423829,"threshold_uncertainty_score":0.3804899,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01156842414867016,"score_gpt":0.3090482567785854,"score_spread":0.2974798326299152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}